High-molecular-weight Fucoidan exerts an immune-enhancing effect in RAW 264.7 cells and cyclophosphamide-induced immunosuppression rat by altering the gut microbiome
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112677 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Eun-Jung Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Food and Nutrition, College of BioNano Technology, Gachon University, Seongnam, Gyeonggi-do 13120, Republic of Korea; Institute for Agi…. Hauptthemen laut MEDLINE: Polysaccharides, Cyclophosphamide, Gastrointestinal Microbiome, NF-kappa B. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
High-molecular-weight fucoidan (Fucoidan P), sourced from Undaria pinnatifida exhibits several health benefits, including immunomodulation. However, the mechanisms underlying the immune-enhancing effects of Fucoidan P remain unclear. Here, we investigated the immune-enhancing effects and the potential mechanisms of Fucoidan P using RAW 264.7 macrophages and cyclophosphamide (CP)-induced immunosuppression rat model. In macrophages, Fucoidan P showed dose-dependent stimulation by increasing cell proliferation, nitric oxide production, and gene expression of inducible nitric oxide synthase, cyclooxygenase-2, and proinflammatory cytokines. These effects are mediated through the activation of the nuclear factor-kappa B (NF-κB) signaling pathway. Moreover, orally administered Fucoidan P was evaluated in immunosuppressed rats treated with CP. Fucoidan P administration increased hematological values and natural killer cell activity, and positively affected nitrite and prostaglandin E2 levels. The Fucoidan P treatment groups exhibited improved serum cytokine levels as well as splenic and intestinal cytokine mRNA expression compared to the model group. Fucoidan P also mitigated splenic damage and increased the phosphorylation of NF-κB and NF-κB inhibitor alpha (IκBα). Furthermore, Fucoidan P treatment altered the gut microbiota composition, enhancing the alpha diversity, evenness, and abundance of Bacteroidetes, which are associated with immune function. Taken together, our findings suggest that Fucoidan P exerts beneficial effects on immune function by activating NF-κB and modulating gut microbiota. These findings suggested its potential as a therapeutic agent for immune enhancement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Food and Nutrition, College of BioNano Technology, Gachon University, Seongnam, Gyeonggi-do 13120, Republic of Korea; Institute for Aging and Clinical Nutrition Research, Gachon University, Seongnam, Gyeon…
- Department of Food Science and Biotechnology, College of BioNano Technology, Gachon University, Seongnam, Gyeonggi-do 13120, Republic of Korea.
- Department of Food and Nutrition, College of BioNano Technology, Gachon University, Seongnam, Gyeonggi-do 13120, Republic of Korea.
Zitieren
APA
Park, E. J., Kim, J. Y., Jaiswal, V., Park, H. S., Ki, D. B., Lee, Y. S., & Lee, H. J. (2024). High-molecular-weight Fucoidan exerts an immune-enhancing effect in RAW 264.7 cells and cyclophosphamide-induced immunosuppression rat by altering the gut microbiome. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112677
Vancouver
Park EJ, Kim JY, Jaiswal V, Park HS, Ki DB, Lee YS, et al. High-molecular-weight Fucoidan exerts an immune-enhancing effect in RAW 264.7 cells and cyclophosphamide-induced immunosuppression rat by altering the gut microbiome. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112677
BibTeX
@article{Park2024,
author = {Park, Eun-Jung and Kim, Jong-Yeon and Jaiswal, Varun and Park, Hae-Sun and Ki, Dan-Bi and Lee, You-Suk and Lee, Hae-Jeung},
title = {High-molecular-weight Fucoidan exerts an immune-enhancing effect in RAW 264.7 cells and cyclophosphamide-induced immunosuppression rat by altering the gut microbiome},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112677}
}
EUVIMED